| Totem Lake Vision Center | |
|
11830 Ne 128th St Ste 1, Kirkland, WA 98034-7202 | |
| (425) 821-8900 | |
| (425) 814-9782 |
| Full Name | Totem Lake Vision Center |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 11830 Ne 128th St Ste 1, Kirkland, Washington |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235317637 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | OD00004018 (Washington) | Primary |
| Provider Name | David L Kading |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1013029719 PECOS PAC ID: 5496714925 Enrollment ID: I20050929000528 |
News Archive
Researchers have identified a new mechanism by which inflammation can spread throughout the brain after injury. This mechanism may explain the widespread and long-lasting inflammation that occurs after traumatic brain injury, and may play a role in other neurodegenerative diseases.
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to an international collaboration of researchers. Their finding sheds new light on the process that makes cancer a deadly disease.
Novartis announced today that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer compounds for the treatment of NASH, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, and a Ketohexokinase (KHK) Inhibitor (PF-06835919).
Emdeon Inc., a leading provider of healthcare revenue and payment cycle management solutions, today announced it has achieved compliance with the CAQH® Committee on Operating Rules for Information Exchange (CORE) Phase II rules. CAQH, a nonprofit alliance of health plans and trade associations, is a catalyst for industry collaboration on initiatives that simplify healthcare administration for health plans and providers, resulting in a better care experience for patients and caregivers. Emdeon achieved CORE Phase I compliance in March 2007.
› Verified 7 days ago
| Provider Name | Kristi M Kading |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1366510737 PECOS PAC ID: 7214997766 Enrollment ID: I20080204000131 |
News Archive
Researchers have identified a new mechanism by which inflammation can spread throughout the brain after injury. This mechanism may explain the widespread and long-lasting inflammation that occurs after traumatic brain injury, and may play a role in other neurodegenerative diseases.
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to an international collaboration of researchers. Their finding sheds new light on the process that makes cancer a deadly disease.
Novartis announced today that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer compounds for the treatment of NASH, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, and a Ketohexokinase (KHK) Inhibitor (PF-06835919).
Emdeon Inc., a leading provider of healthcare revenue and payment cycle management solutions, today announced it has achieved compliance with the CAQH® Committee on Operating Rules for Information Exchange (CORE) Phase II rules. CAQH, a nonprofit alliance of health plans and trade associations, is a catalyst for industry collaboration on initiatives that simplify healthcare administration for health plans and providers, resulting in a better care experience for patients and caregivers. Emdeon achieved CORE Phase I compliance in March 2007.
› Verified 7 days ago
| Provider Name | Katherine Y Shen |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1922315282 PECOS PAC ID: 4587852322 Enrollment ID: I20120117000071 |
News Archive
Researchers have identified a new mechanism by which inflammation can spread throughout the brain after injury. This mechanism may explain the widespread and long-lasting inflammation that occurs after traumatic brain injury, and may play a role in other neurodegenerative diseases.
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to an international collaboration of researchers. Their finding sheds new light on the process that makes cancer a deadly disease.
Novartis announced today that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer compounds for the treatment of NASH, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, and a Ketohexokinase (KHK) Inhibitor (PF-06835919).
Emdeon Inc., a leading provider of healthcare revenue and payment cycle management solutions, today announced it has achieved compliance with the CAQH® Committee on Operating Rules for Information Exchange (CORE) Phase II rules. CAQH, a nonprofit alliance of health plans and trade associations, is a catalyst for industry collaboration on initiatives that simplify healthcare administration for health plans and providers, resulting in a better care experience for patients and caregivers. Emdeon achieved CORE Phase I compliance in March 2007.
› Verified 7 days ago
| Provider Name | Charissa Young |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1184976417 PECOS PAC ID: 5890083794 Enrollment ID: I20161010000494 |
News Archive
Researchers have identified a new mechanism by which inflammation can spread throughout the brain after injury. This mechanism may explain the widespread and long-lasting inflammation that occurs after traumatic brain injury, and may play a role in other neurodegenerative diseases.
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to an international collaboration of researchers. Their finding sheds new light on the process that makes cancer a deadly disease.
Novartis announced today that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer compounds for the treatment of NASH, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, and a Ketohexokinase (KHK) Inhibitor (PF-06835919).
Emdeon Inc., a leading provider of healthcare revenue and payment cycle management solutions, today announced it has achieved compliance with the CAQH® Committee on Operating Rules for Information Exchange (CORE) Phase II rules. CAQH, a nonprofit alliance of health plans and trade associations, is a catalyst for industry collaboration on initiatives that simplify healthcare administration for health plans and providers, resulting in a better care experience for patients and caregivers. Emdeon achieved CORE Phase I compliance in March 2007.
› Verified 7 days ago
| Provider Name | Tracy M Lin |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1699138198 PECOS PAC ID: 7911264601 Enrollment ID: I20171205003083 |
News Archive
Researchers have identified a new mechanism by which inflammation can spread throughout the brain after injury. This mechanism may explain the widespread and long-lasting inflammation that occurs after traumatic brain injury, and may play a role in other neurodegenerative diseases.
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to an international collaboration of researchers. Their finding sheds new light on the process that makes cancer a deadly disease.
Novartis announced today that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer compounds for the treatment of NASH, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, and a Ketohexokinase (KHK) Inhibitor (PF-06835919).
Emdeon Inc., a leading provider of healthcare revenue and payment cycle management solutions, today announced it has achieved compliance with the CAQH® Committee on Operating Rules for Information Exchange (CORE) Phase II rules. CAQH, a nonprofit alliance of health plans and trade associations, is a catalyst for industry collaboration on initiatives that simplify healthcare administration for health plans and providers, resulting in a better care experience for patients and caregivers. Emdeon achieved CORE Phase I compliance in March 2007.
› Verified 7 days ago
| Provider Name | Sarah Paige Henderson |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1558882712 PECOS PAC ID: 6305103961 Enrollment ID: I20171206002933 |
News Archive
Researchers have identified a new mechanism by which inflammation can spread throughout the brain after injury. This mechanism may explain the widespread and long-lasting inflammation that occurs after traumatic brain injury, and may play a role in other neurodegenerative diseases.
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to an international collaboration of researchers. Their finding sheds new light on the process that makes cancer a deadly disease.
Novartis announced today that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer compounds for the treatment of NASH, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, and a Ketohexokinase (KHK) Inhibitor (PF-06835919).
Emdeon Inc., a leading provider of healthcare revenue and payment cycle management solutions, today announced it has achieved compliance with the CAQH® Committee on Operating Rules for Information Exchange (CORE) Phase II rules. CAQH, a nonprofit alliance of health plans and trade associations, is a catalyst for industry collaboration on initiatives that simplify healthcare administration for health plans and providers, resulting in a better care experience for patients and caregivers. Emdeon achieved CORE Phase I compliance in March 2007.
› Verified 7 days ago
| Provider Name | Andrew R Fischer |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1790281905 PECOS PAC ID: 5395091128 Enrollment ID: I20180709001714 |
News Archive
Researchers have identified a new mechanism by which inflammation can spread throughout the brain after injury. This mechanism may explain the widespread and long-lasting inflammation that occurs after traumatic brain injury, and may play a role in other neurodegenerative diseases.
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to an international collaboration of researchers. Their finding sheds new light on the process that makes cancer a deadly disease.
Novartis announced today that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer compounds for the treatment of NASH, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, and a Ketohexokinase (KHK) Inhibitor (PF-06835919).
Emdeon Inc., a leading provider of healthcare revenue and payment cycle management solutions, today announced it has achieved compliance with the CAQH® Committee on Operating Rules for Information Exchange (CORE) Phase II rules. CAQH, a nonprofit alliance of health plans and trade associations, is a catalyst for industry collaboration on initiatives that simplify healthcare administration for health plans and providers, resulting in a better care experience for patients and caregivers. Emdeon achieved CORE Phase I compliance in March 2007.
› Verified 7 days ago
| Provider Name | Courtney L Melchione |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1598115271 PECOS PAC ID: 3577891233 Enrollment ID: I20190820002300 |
News Archive
Researchers have identified a new mechanism by which inflammation can spread throughout the brain after injury. This mechanism may explain the widespread and long-lasting inflammation that occurs after traumatic brain injury, and may play a role in other neurodegenerative diseases.
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to an international collaboration of researchers. Their finding sheds new light on the process that makes cancer a deadly disease.
Novartis announced today that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer compounds for the treatment of NASH, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, and a Ketohexokinase (KHK) Inhibitor (PF-06835919).
Emdeon Inc., a leading provider of healthcare revenue and payment cycle management solutions, today announced it has achieved compliance with the CAQH® Committee on Operating Rules for Information Exchange (CORE) Phase II rules. CAQH, a nonprofit alliance of health plans and trade associations, is a catalyst for industry collaboration on initiatives that simplify healthcare administration for health plans and providers, resulting in a better care experience for patients and caregivers. Emdeon achieved CORE Phase I compliance in March 2007.
› Verified 7 days ago
| Provider Name | Stephanie J He |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1417452921 PECOS PAC ID: 6709212178 Enrollment ID: I20200203001042 |
News Archive
Researchers have identified a new mechanism by which inflammation can spread throughout the brain after injury. This mechanism may explain the widespread and long-lasting inflammation that occurs after traumatic brain injury, and may play a role in other neurodegenerative diseases.
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to an international collaboration of researchers. Their finding sheds new light on the process that makes cancer a deadly disease.
Novartis announced today that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer compounds for the treatment of NASH, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, and a Ketohexokinase (KHK) Inhibitor (PF-06835919).
Emdeon Inc., a leading provider of healthcare revenue and payment cycle management solutions, today announced it has achieved compliance with the CAQH® Committee on Operating Rules for Information Exchange (CORE) Phase II rules. CAQH, a nonprofit alliance of health plans and trade associations, is a catalyst for industry collaboration on initiatives that simplify healthcare administration for health plans and providers, resulting in a better care experience for patients and caregivers. Emdeon achieved CORE Phase I compliance in March 2007.
› Verified 7 days ago
| Provider Name | Sydney Kapp |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1487290763 PECOS PAC ID: 3375965643 Enrollment ID: I20200616001300 |
News Archive
Researchers have identified a new mechanism by which inflammation can spread throughout the brain after injury. This mechanism may explain the widespread and long-lasting inflammation that occurs after traumatic brain injury, and may play a role in other neurodegenerative diseases.
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to an international collaboration of researchers. Their finding sheds new light on the process that makes cancer a deadly disease.
Novartis announced today that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer compounds for the treatment of NASH, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, and a Ketohexokinase (KHK) Inhibitor (PF-06835919).
Emdeon Inc., a leading provider of healthcare revenue and payment cycle management solutions, today announced it has achieved compliance with the CAQH® Committee on Operating Rules for Information Exchange (CORE) Phase II rules. CAQH, a nonprofit alliance of health plans and trade associations, is a catalyst for industry collaboration on initiatives that simplify healthcare administration for health plans and providers, resulting in a better care experience for patients and caregivers. Emdeon achieved CORE Phase I compliance in March 2007.
› Verified 7 days ago
| Provider Name | Jasmeen Kaur Bhangu |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1780209304 PECOS PAC ID: 8820410038 Enrollment ID: I20200616003537 |
News Archive
Researchers have identified a new mechanism by which inflammation can spread throughout the brain after injury. This mechanism may explain the widespread and long-lasting inflammation that occurs after traumatic brain injury, and may play a role in other neurodegenerative diseases.
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to an international collaboration of researchers. Their finding sheds new light on the process that makes cancer a deadly disease.
Novartis announced today that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer compounds for the treatment of NASH, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, and a Ketohexokinase (KHK) Inhibitor (PF-06835919).
Emdeon Inc., a leading provider of healthcare revenue and payment cycle management solutions, today announced it has achieved compliance with the CAQH® Committee on Operating Rules for Information Exchange (CORE) Phase II rules. CAQH, a nonprofit alliance of health plans and trade associations, is a catalyst for industry collaboration on initiatives that simplify healthcare administration for health plans and providers, resulting in a better care experience for patients and caregivers. Emdeon achieved CORE Phase I compliance in March 2007.
› Verified 7 days ago
| Provider Name | Selena Huang |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1790359263 PECOS PAC ID: 2961808886 Enrollment ID: I20210901001061 |
News Archive
Researchers have identified a new mechanism by which inflammation can spread throughout the brain after injury. This mechanism may explain the widespread and long-lasting inflammation that occurs after traumatic brain injury, and may play a role in other neurodegenerative diseases.
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to an international collaboration of researchers. Their finding sheds new light on the process that makes cancer a deadly disease.
Novartis announced today that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer compounds for the treatment of NASH, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, and a Ketohexokinase (KHK) Inhibitor (PF-06835919).
Emdeon Inc., a leading provider of healthcare revenue and payment cycle management solutions, today announced it has achieved compliance with the CAQH® Committee on Operating Rules for Information Exchange (CORE) Phase II rules. CAQH, a nonprofit alliance of health plans and trade associations, is a catalyst for industry collaboration on initiatives that simplify healthcare administration for health plans and providers, resulting in a better care experience for patients and caregivers. Emdeon achieved CORE Phase I compliance in March 2007.
› Verified 7 days ago
| Provider Name | Megan Schmauder |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1922682509 PECOS PAC ID: 6608273149 Enrollment ID: I20210924002726 |
News Archive
Researchers have identified a new mechanism by which inflammation can spread throughout the brain after injury. This mechanism may explain the widespread and long-lasting inflammation that occurs after traumatic brain injury, and may play a role in other neurodegenerative diseases.
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to an international collaboration of researchers. Their finding sheds new light on the process that makes cancer a deadly disease.
Novartis announced today that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer compounds for the treatment of NASH, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, and a Ketohexokinase (KHK) Inhibitor (PF-06835919).
Emdeon Inc., a leading provider of healthcare revenue and payment cycle management solutions, today announced it has achieved compliance with the CAQH® Committee on Operating Rules for Information Exchange (CORE) Phase II rules. CAQH, a nonprofit alliance of health plans and trade associations, is a catalyst for industry collaboration on initiatives that simplify healthcare administration for health plans and providers, resulting in a better care experience for patients and caregivers. Emdeon achieved CORE Phase I compliance in March 2007.
› Verified 7 days ago
| Provider Name | Lauren Downey |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1720710569 PECOS PAC ID: 4183007495 Enrollment ID: I20220819000914 |
News Archive
Researchers have identified a new mechanism by which inflammation can spread throughout the brain after injury. This mechanism may explain the widespread and long-lasting inflammation that occurs after traumatic brain injury, and may play a role in other neurodegenerative diseases.
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to an international collaboration of researchers. Their finding sheds new light on the process that makes cancer a deadly disease.
Novartis announced today that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer compounds for the treatment of NASH, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, and a Ketohexokinase (KHK) Inhibitor (PF-06835919).
Emdeon Inc., a leading provider of healthcare revenue and payment cycle management solutions, today announced it has achieved compliance with the CAQH® Committee on Operating Rules for Information Exchange (CORE) Phase II rules. CAQH, a nonprofit alliance of health plans and trade associations, is a catalyst for industry collaboration on initiatives that simplify healthcare administration for health plans and providers, resulting in a better care experience for patients and caregivers. Emdeon achieved CORE Phase I compliance in March 2007.
› Verified 7 days ago
| Provider Name | Nina Wang |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1831877026 PECOS PAC ID: 0143683292 Enrollment ID: I20230823001085 |
News Archive
Researchers have identified a new mechanism by which inflammation can spread throughout the brain after injury. This mechanism may explain the widespread and long-lasting inflammation that occurs after traumatic brain injury, and may play a role in other neurodegenerative diseases.
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to an international collaboration of researchers. Their finding sheds new light on the process that makes cancer a deadly disease.
Novartis announced today that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer compounds for the treatment of NASH, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, and a Ketohexokinase (KHK) Inhibitor (PF-06835919).
Emdeon Inc., a leading provider of healthcare revenue and payment cycle management solutions, today announced it has achieved compliance with the CAQH® Committee on Operating Rules for Information Exchange (CORE) Phase II rules. CAQH, a nonprofit alliance of health plans and trade associations, is a catalyst for industry collaboration on initiatives that simplify healthcare administration for health plans and providers, resulting in a better care experience for patients and caregivers. Emdeon achieved CORE Phase I compliance in March 2007.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Totem Lake Vision Center 11830 Ne 128th St Ste 1, Kirkland, WA 98034-7202 Ph: (425) 821-8900 | Totem Lake Vision Center 11830 Ne 128th St Ste 1, Kirkland, WA 98034-7202 Ph: (425) 821-8900 |
News Archive
Researchers have identified a new mechanism by which inflammation can spread throughout the brain after injury. This mechanism may explain the widespread and long-lasting inflammation that occurs after traumatic brain injury, and may play a role in other neurodegenerative diseases.
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to an international collaboration of researchers. Their finding sheds new light on the process that makes cancer a deadly disease.
Novartis announced today that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer compounds for the treatment of NASH, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, and a Ketohexokinase (KHK) Inhibitor (PF-06835919).
Emdeon Inc., a leading provider of healthcare revenue and payment cycle management solutions, today announced it has achieved compliance with the CAQH® Committee on Operating Rules for Information Exchange (CORE) Phase II rules. CAQH, a nonprofit alliance of health plans and trade associations, is a catalyst for industry collaboration on initiatives that simplify healthcare administration for health plans and providers, resulting in a better care experience for patients and caregivers. Emdeon achieved CORE Phase I compliance in March 2007.
› Verified 7 days ago
David L Kading, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 11830 Ne 128th St, Ste 1, Kirkland, WA 98034 Phone: 425-821-8900 Fax: 425-814-9782 | |
Xue Li, Optometrist Medicare: Not Enrolled in Medicare Practice Location: 8629 120th Ave Ne, Kirkland, WA 98033 Phone: 425-827-1693 | |
Patricia Miesook Oh, O.D., M.S. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 11800 Ne 128th St Ste 300, Kirkland, WA 98034 Phone: 425-821-8004 Fax: 425-820-9860 | |
Dr. Ashley Nichole Darton, DOCTOR OF OPTOMETRY Optometrist Medicare: Medicare Enrolled Practice Location: 134 Central Way, Kirkland, WA 98033 Phone: 425-889-2020 | |
Dr. Kelsey Yared, OD Optometrist Medicare: Medicare Enrolled Practice Location: 400 Urban Plz Ste 110, Kirkland, WA 98033 Phone: 425-403-2020 | |
Charissa Young, O.D. Optometrist Medicare: May Accept Medicare Assignments Practice Location: 11830 Ne 128th St Ste 1, Kirkland, WA 98034 Phone: 425-821-8900 | |
Dr. Karenjeet Sahota, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 9726 Ne 119th Way, Kirkland, WA 98034 Phone: 425-821-2010 Fax: 425-821-2011 |